Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Ablynx has generated Nanobodies® against more than 100 different disease targets and has characterised potent antagonists in vitro against 20 different targets.
The Company and its collaborators have obtained positive in vivo efficacy data from animal studies in five major therapeutic programmes in four disease areas. Importantly, Ablynx has shown the absence of any detectable immunogenicity for its Nanobody® development candidates in advanced primate studies. Ablynx reported the final positive results from its Phase I study in December 2007 and in May 2008 Ablynx has initiated a Phase Ib multiple-dose study directly in the target patient population rather than healthy volunteers for ALX-0081. One other programme is in advanced preclinical development.
Ablynx has ongoing research collaborations and significant, partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Novartis, P&G Pharma and Wyeth Pharmaceuticals. Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies® through these collaborations as well as through its own internal discovery programmes.
Ablynx has a strong and broad IP position and is the only company in the world with granted US and European patents that describe the composition of matter of Nanobodies® (the “Hamers patents”), representing a distinct and unique position in the complex field of antibody-derived therapeutics. Ablynx’s patent estate currently encompasses more than 200 granted patents and patent applications in about 50 patent families.